Gennova has been working on self-amplifying mRNA vaccine. mRNA vaccines use body’s machinery to make antigenic protein rather ...

Bristol Myers Squibb plans to close its viral vector production facility in Libertyville, IL according to a BMS spokesperson ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and ...

From rare diseases to common chronic conditions, advances in viral vector-based gene therapies are bringing exciting new clinical possibilities to the table. But current costs per dose land as ...

Welcome to the Moderna first-quarter 2025 conference call. (Operator Instructions) Please be advised, today's conference is being recorded. I would now like to hand the conference over to your ...

From STAT’s Jason Mast: Moderna said this morning in its earnings report it planned to cut costs by around $1.5 billion by 2027, adding $700 million to $1 billion on top of more modest cuts ...

Moderna Q1 EPS loss of $(2.52) beat estimates, while revenue hit $108 million, topping forecast despite falling from last year. Spikevax sales reached $84 million in Q1; RSV vaccine mRESVIA saw $2 ...

With the bird flu infecting more than 135 herds and spreading to 3 people this year, the US federal government will be investing $176 million to expedite the creation of an influenza vaccine.

(Reuters) -Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's cost-cutting efforts following waning post-pandemic demand for its COVID ...

In this article, we will take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other worst performing stocks this year. After a two-year surge of 53%, marking the best performance for ...